[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
December 1, 1999

Parkinson Treatment Approval

Author Affiliations
 

Not Available

Not Available

JAMA. 1999;282(21):1995. doi:10.1001/jama.282.21.1995-JFD90010-3-1

The FDA has approved entacapone (COMTAN, Orion Corp, Scotch Plains, NJ), a new catechol-O-methyltransferase (COMT) inhibitor, as an adjunct to levodopa/carbidopa for patients with Parkinson disease who experience end-of-dose worsening. Entacapone's ability to inhibit COMT, one of the enzymes responsible for the metabolism of dopamine, results in greater and more sustained plasma levels of dopamine than levodopa/carbidopa when the latter is given alone. One 200-mg entacapone tablet is administered concomitantly with each dose of levodopa/carbidopa, up to a maximum of 8 doses per day (1600 mg/d).

First Page Preview View Large
First page PDF preview
First page PDF preview
×